BRIEF-Amgen announces Erenumab significantly reduces monthly migraine days in patients with episodic migraine in second phase 3 study

* Amgen announces Erenumab significantly reduces monthly migraine days in patients with episodic migraine in second phase 3 study
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.